Related Experiment Video
Updated: Jun 10, 2026
10:03
Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice
Published on: November 18, 2022
Immune intervention in children with type 1 diabetes
1Department of Clinical and Experimental Medicine, Division of Pediatrics, Faculty of Health Sciences, Linköping University, Linköping, Sweden. Johnny.Ludvigsson@li.o.se
Current Diabetes Reports
|July 30, 2010
Summary
This study explores autoimmune disease treatments, highlighting B cell therapies and autoantigen strategies like GAD65 for potential tolerance induction. Future research aims to combine immune modulation with beta cell protection for improved outcomes.
Area of Science:
- Immunology
- Autoimmune Diseases
- Therapeutic Strategies
Background:
- Autoimmune processes involve both T cells and B cells.
- Current antibody therapies (anti-CD3, anti-CD20) show efficacy but require refinement to minimize adverse events.
- Autoantigen-based tolerance induction presents a promising therapeutic avenue.
Purpose of the Study:
- To review current and potential immunomodulatory strategies for autoimmune diseases.
- To evaluate the efficacy and safety of novel approaches like GAD65 and insulin B chain administration.
- To explore combination therapies for enhanced treatment outcomes and beta cell protection.
Main Methods:
- Review of existing literature on immunotherapies for autoimmune conditions.
- Analysis of studies investigating autoantigen-specific treatments.
- Discussion of adjunctive strategies for beta cell protection and regeneration.
Main Results:
- Monoclonal antibodies targeting CD3 and CD20 demonstrate therapeutic potential.
- GAD65 treatment has shown efficacy without adverse events.
- Insulin B chain administration exhibits notable immunologic effects.
Conclusions:
- Refining existing antibody therapies and exploring autoantigen-based tolerance are key.
- Combination therapies involving immune intervention, beta cell protection, and regeneration hold promise for future treatment or cure.
- Prevention of autoimmune diseases may become a realistic goal.
More Related Videos
Related Concept Videos
01:12Type I Diabetes I: Introduction
Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
01:22Diabetes Mellitus: Overview and Type I Subtype
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
01:26Type I Diabetes II: Pathophysiology
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:22Diabetes Mellitus: Type 2 and Gestational
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...